NBTXR3 + anti-PD1

About Nanobiotix

Nanobiotix is a French biotechnology company developing novel nanotherapeutics that aim to revolutionize cancer treatment by enhancing the efficacy of radiotherapy. Its core technology involves hafnium oxide nanoparticles (NBTXR3) that, when activated by radiotherapy, produce a significant increase in tumor cell death and may stimulate an adaptive immune response. The company has achieved key milestones with positive Phase 3 results in soft tissue sarcoma and is advancing clinical programs across multiple solid tumor indications, supported by strategic partnerships with global leaders like Johnson & Johnson and LianBio.

About Nanobiotix

Nanobiotix is a French biotechnology company developing novel nanotherapeutics that aim to revolutionize cancer treatment by enhancing the efficacy of radiotherapy. Its core technology involves hafnium oxide nanoparticles (NBTXR3) that, when activated by radiotherapy, produce a significant increase in tumor cell death and may stimulate an adaptive immune response. The company has achieved key milestones with positive Phase 3 results in soft tissue sarcoma and is advancing clinical programs across multiple solid tumor indications, supported by strategic partnerships with global leaders like Johnson & Johnson and LianBio.

Therapeutic Areas